# A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes

> **NCT06326047** · PHASE2 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 299 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** NNC0519-0130
- **DRUG:** Placebo
- **DRUG:** Trizepatide

## Key facts

- **NCT ID:** NCT06326047
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-03-18
- **Primary completion:** 2025-09-19
- **Final completion:** 2025-10-13
- **Target enrollment:** 299 (ACTUAL)
- **Last updated:** 2025-12-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06326047

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06326047, "A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06326047. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*